Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2% – Should You Sell?

Janux Therapeutics, Inc. (NASDAQ:JANX) shares were down 4.2% during mid-day trading on Tuesday . The stock traded as low as $40.54 and last traded at $40.29. Approximately 99,568 shares were traded during trading, a decline of 91% from the average daily volume of 1,068,532 shares. The stock had previously closed at $42.07.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. UBS Group started coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Stifel Nicolaus boosted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, BTIG Research upped their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Trading Down 8.9 %

The business has a 50 day simple moving average of $51.30 and a two-hundred day simple moving average of $48.39. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -34.77 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, CEO David Alan Campbell sold 15,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the sale, the chief executive officer now directly owns 242,054 shares of the company’s stock, valued at approximately $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,668 shares of company stock valued at $4,872,515 in the last ninety days. Corporate insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Plato Investment Management Ltd grew its stake in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Avanza Fonder AB bought a new stake in Janux Therapeutics in the 4th quarter valued at about $139,000. Chicago Capital LLC acquired a new position in Janux Therapeutics during the 4th quarter valued at about $230,000. Finally, AQR Capital Management LLC bought a new position in Janux Therapeutics in the 2nd quarter worth about $215,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.